True Binding
Expanded Access Program
Hope for those who need it most.
TrueBinding offers an Expanded Access Program (also known as compassionate use) for patients with Alzheimer’s disease who have no remaining treatment options and are not eligible for clinical trials. This program provides access to TB006—a promising investigational therapy—under carefully monitored conditions.
What is TB006?
A new approach in Alzheimer’s treatment.
TB006 is a humanized monoclonal antibody being developed by TrueBinding to treat Alzheimer’s disease. It specifically targets galectin-3 (Gal3), a protein linked to the formation of amyloid plaques—a major contributor to Alzheimer’s progression.
How It Works
Targeting the source of neurodegeneration.
TB006 binds to galectin-3, preventing it from encouraging the aggregation of amyloid-beta (Aβ) proteins. By stopping this clumping process, TB006 may also reduce the formation of tau tangles—two major hallmarks of Alzheimer’s disease.
Blocks Gal3
Prevents galectin-3 from promoting amyloid plaque formation
Reduces Aβ and Tau
Lowers buildup of amyloid-beta plaques and tau tangles
Slows or Reverses Decline
Aims to slow progression and improve cognitive function
Clinical Trial Highlights
Promising results across multiple phases.
TB006 has been evaluated in a Phase 1b/2 clinical trial, showing early signs of cognitive benefit and disease slowing in patients with mild to severe Alzheimer’s disease.
Improvements observed in Mini-Mental State Examination (MMSE) scores
Potential benefit in slowing or reducing overall cognitive decline
Continued research in both Alzheimer’s and acute ischemic stroke populations
Potential Benefits of TB006
Restoring function and preserving memory.
Initial results suggest TB006 may offer several therapeutic benefits:
Slows Alzheimer’s disease progression
May improve cognitive function
Potential to reverse aspects of neurological damage
Frequently Asked Questions
Common questions about our treatment.
Is TB006 safe?
Yes, early safety trials suggest that TB006 is generally well-tolerated.
Some patients may experience mild infusion reactions such as fever, rash, or nausea. These side effects are usually manageable under medical supervision.
Is TB006 being studied for other conditions?
Yes, TB006 is also being researched beyond Alzheimer’s disease.
It is currently in a Phase 2 trial for acute ischemic stroke, and TrueBinding continues to explore its potential across other neurological conditions.
start your wellness journey
Ready to book your next IV treatment?
Schedule your session and experience the difference.